ADR Biomedical Holdings (TSE:3750) Change In Receivables: 円0.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:3750 ADR Biomedical Holdings Inc TSE:3750
27 GF Score
Price 円826.00
GF Value 円38.92
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is ADR Biomedical Holdings Change In Receivables?

ADR Biomedical Holdings TSE:3750 +0.49% 27 Change In Receivables is 円0.0 Mil as of Mar. 2026. GuruFocus rates TSE:3750 with a GF Score™ of 27/100 and a GF Value™ of 円38.92 (Significantly Overvalued). The stock has 7 warning signs investors should review.

ADR Biomedical Holdings's change in receivables for the quarter that ended in Mar. 2026 was 円0.0 Mil. It means ADR Biomedical Holdings's Accounts Receivable stayed the same from Dec. 2025 to Mar. 2026 .

ADR Biomedical Holdings's change in receivables for the fiscal year that ended in Mar. 2026 was 円-143.8 Mil. It means ADR Biomedical Holdings's Accounts Receivable increased by 円143.8 Mil from Mar. 2025 to Mar. 2026 .

ADR Biomedical Holdings's Accounts Receivable for the quarter that ended in Mar. 2026 was 円8.2 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. ADR Biomedical Holdings's Days Sales Outstanding for the three months ended in Mar. 2026 was 43.21.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. ADR Biomedical Holdings's liquidation value for the three months ended in Mar. 2026 was 円-180.8 Mil.

ADR Biomedical Holdings  (TSE:3750) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

ADR Biomedical Holdings's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=8.188/17.292*91
=43.21

2. In Ben Graham's calculation of liquidation value, ADR Biomedical Holdings's accounts receivable are only considered to be worth 75% of book value:

ADR Biomedical Holdings's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=125.901-346.032+0.75 * 8.188+0.5 * 66.41
=-180.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADR Biomedical Holdings Change In Receivables Related Terms

ADR Biomedical Holdings Change In Receivables Historical Data

* Premium members only.

The historical data trend for ADR Biomedical Holdings's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADR Biomedical Holdings Change In Receivables Chart

ADR Biomedical Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 3.41 102.88 -143.81

ADR Biomedical Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:3750
27GF Score
ADR Biomedical Holdings Inc TSE:3750
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ADR Biomedical Holdings Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of 円0.0 Mil mean?
ADR Biomedical Holdings (TSE:3750) has a Change In Receivables of 円0.0 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for ADR Biomedical Holdings and its competitors.
Is ADR Biomedical Holdings' Change In Receivables too high?
ADR Biomedical Holdings' current Change In Receivables is 円0.0 Mil. Overall, ADR Biomedical Holdings has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ADR Biomedical Holdings' Change In Receivables compare to VRTX and REGN?
ADR Biomedical Holdings' Change In Receivables of 円0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for ADR Biomedical Holdings and its competitors. ADR Biomedical Holdings's current Change In Receivables is 円0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADR Biomedical Holdings stock overvalued right now?
Based on GuruFocus' analysis, ADR Biomedical Holdings (TSE:3750) is currently considered Significantly Overvalued. The stock's GF Value™ is 円38.92, compared to a current price of 円826.00 — trading 2022.3% above its estimated fair value. The current Change In Receivables is 円0.0 Mil. ADR Biomedical Holdings' overall GF Score™ is 27/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For ADR Biomedical Holdings (TSE:3750), the current Change In Receivables is 円0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?

Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued. The current stock price of 円826.00 is trading 2022.3% above its estimated GF Value™ of 円38.92. GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.

Key valuation signals for TSE:3750:

  • Change In Receivables: 円0.0 Mil
  • GF Value™: 円38.92 vs. price of 円826.00 (2022.3% above fair value)
  • GF Score™: 27/100 with 7 warning signs

No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ADR Biomedical Holdings Business Description

Address 1-1-1 Otemachi, Otemachi Park Building, Chiyoda-ku, Tokyo, JPN, 100-0004
ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.
27GF Score

Get the complete analysis for TSE:3750

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円826.00
Price
円38.92
GF Value